US Biochip Product and Services Market is driven by Advancement in Microarray Technology
Key players operating in the US biochip product and services market size are Galderma SA, Allergan plc (AbbVie Inc.), Bayer AG, Pfizer Inc., Leo Pharma A/S, Sol-Gel Technologies Ltd., Foamix Pharmaceuticals Ltd., Mayne Pharma, Group Limited, AnaptysBio, Inc., Mylan N.V. Growing demand for personalized medicine and companion diagnostics is driving the biochip market growth. Biochips enable high-throughput screening, early detection of diseases, and selection of targeted drug therapies suited for individual patients.
The Midwest region of the United States, consisting of states like Illinois, Ohio, Missouri, etc. is expected to witness the fastest value growth within the overall US biochip market during 2024-2031. This growth can be attributed to rising focus on development of personalized medicines and expansion plans of several big biochip players in Midwest cities. For instance, Galderma recently invested in expanding its R&D facility in Ohio to strengthen its biochip based skin research. Similarly, Bayer opened a new biochip research center in St Louis, Missouri in 2023.
Get more insights on US Biochip Product and Services Market
Also Read Related Article on Idiopathic Hypersomnia Treatment
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian